Shared on27 Oct 25Fair value Increased 8.62%
Analysts have raised their price target for Medistim from NOK 290 to NOK 315, citing improved revenue growth projections and higher expected profit margins. What's in the News Medistim completed the repurchase of 189,224 shares, representing 1.04% of its outstanding shares, for a total of NOK 12.5 million.
Shared on09 Sep 25Fair value Increased 14%
The significant upward revision in Medistim's price target is driven by higher consensus revenue growth forecasts and a rising future P/E multiple, resulting in the fair value increasing to NOK290.00. Valuation Changes Summary of Valuation Changes for Medistim The Consensus Analyst Price Target has significantly risen from NOK255.00 to NOK290.00.
Shared on25 Aug 25Fair value Increased 11%
Despite a reduction in consensus revenue growth forecasts and a higher future P/E, analysts have notably raised Medistim’s fair value estimate from NOK230.00 to NOK255.00. Valuation Changes Summary of Valuation Changes for Medistim The Consensus Analyst Price Target has significantly risen from NOK230.00 to NOK255.00.